Skip to content
Business Company News, Medical Health Aged Care

Entrepreneur and athlete backed start-up UAre seeks $1 Million to revolutionise longevity and well-being

Chapter One Advisors 2 mins read

UAre, the innovative longevity business founded by experienced entrepreneurs Marc Pasques, Grant Ellison, and Kendrick Louis, has launched a $1 million seed funding round (post raise valuation of $9 million), with funds to be applied to enabling UAre to scale its unique solution designed to measure and maximise quality of life and longevity for individuals and organisations.

 

Innovative Approach to Longevity

 

UAre consolidates data from the UAre app and various wearable technologies, then standardises it for users, providing insightful data on movement, mindset, relationships, and habits. By leveraging this data, UAre offers personalised recommendations and an estimated life expectancy, helping users make informed decisions to enhance their well-being and longevity.

 

B2B Offering: Enhancing Organisational Performance

 

UAre’s solution is not just for individuals; it also offers significant benefits for organisations. The company provides anonymised aggregated insights that enable businesses to ethically benchmark and improve the performance and longevity of their employees, customers, and members. This ensures that companies can accurately target and maximise their return on investment in human capital. UAre’s premium service bundles for B2B customers include mentoring from elite athletes and epigenetic testing, providing a comprehensive approach to enhancing employee well-being and productivity.

 

“We’re providing businesses with critical insights into their wellbeing programs' effectiveness, guiding them on where to invest next,” said Kendrick Louis. “This seed raise is a significant milestone in our journey to make a meaningful impact on global health and longevity.”

 

Meet the Founders

  • Grant Ellison, a successful entrepreneur, and strategist. Has founded and led multi-national tech businesses through start-up, scale-up, IPO and exit. For more info see: https://www.linkedin.com/in/grantellison/

 

  • Marc Pasques is an experienced customer focused tech leader. Expert in building and managing teams to deliver scalable solutions for multi-national businesses. For more info see: https://www.linkedin.com/in/marcpasques/

 

 

A Growing Market

 

The wearable technology market is expanding rapidly. A recent study by Telsyte revealed that 36% of Australians now own a smartwatch, with the market projected to reach $5.3 billion this year and potentially grow to $6.5 billion by 2029​​. UAre’s innovative approach positions it at the forefront of this growth, offering unique solutions that cater to both individual and organisational needs.

 

Future Prospects

 

“We’re bullish on UAre’s future,” said Grant Ellison. “We forecast a revenue of $30 million by the end of 2026 and an enterprise valuation of $150 million. Our goal is to have 500,000 users and 200 businesses signed up for our application.”

 

By the end of 2024, UAre anticipates having 30 business customers and 50,000 individual members, generating about $1 million in revenue. Growth is expected to be driven by uptake from businesses and investments in premium services such as mentoring from elite athletes and epigenetic testing.

 

About UAre

 

UAre is a pioneering company dedicated to enhancing longevity and well-being through advanced technology and personalised insights. By integrating data from wearable devices and offering tailored recommendations, UAre empowers individuals and organizations to improve their quality of life and achieve their wellness goals.


Contact details:

Kendrick Louis
Co-Founder, UAre
Email: [email protected] 

Media

More from this category

  • Medical Health Aged Care
  • 18/12/2025
  • 22:11
BeOne Medicines Ltd.

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancer FDA Fast Track Designation reflects the…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 19:11
Takeda Pharmaceutical Company Limited

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 12:24
La Trobe University

Cell death discovery could aid cancer treatments

LaTrobe researchers have made a groundbreaking discovery about the way dying cells are cleared from our bodies, which could have important impacts on recovery from diseases including cancer infection and inflammatory diseases. Traditionally, it was believed dying cells were broken into smaller pieces by the cell’s own internal machinery, enabling the pieces to be more easily removed from the body. However the study, led by scientists at the La Trobe Institute for Molecular Science and Research Centre for Extracellular Vesicles found that the process of dying cell fragmentation is actually assisted by neighbouring cells. Published in Science Advances, the study…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.